Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windlas BiotechNSE:WINDLAS -0.08%88 Pretax Margin % is 9.24% as of Jun. 2026, which is 9% below its 10-year median of 10.20. GuruFocus rates NSE:WINDLAS with a GF Score™ of 88/100 and a GF Value™ of ₹978.98 (Fairly Valued). The stock has 4 warning signs investors should review. Among 957 Drug Manufacturers companies, Windlas Biotech ranks better than 55.17% on this metric.
The historical rank and industry rank for Windlas Biotech's Pretax Margin % or its related term are showing as below:
NSE:WINDLAS'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.09 Med: 10.2 Max: 24.93
Current: 9.2
NSE:WINDLAS's Pretax Margin % is ranked better than 55.17% of 957
companies
in the Drug Manufacturers industry
Industry Median: 7.48
vs NSE:WINDLAS: 9.20
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Windlas Biotech Pretax Margin % Related Terms
Windlas Biotech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Pretax Margin % of 9.24% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Windlas Biotech and its competitors. This is near median its historical median of 10.20. Over the past decade, Windlas Biotech's Pretax Margin % has ranged from 5.09 to 24.93. According to the industry distribution chart, Windlas Biotech ranks #429 out of 957 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Windlas Biotech's Pretax Margin % too high?
Windlas Biotech's current Pretax Margin % of 9.24% is near median its 10-year median of 10.20. Over the past 10 years, this metric has ranged from a low of 5.09 to a high of 24.93. The Drug Manufacturers industry median Pretax Margin % is 7.48. Windlas Biotech's value of 9.24% is 23.5% above this industry median. Based on the distribution chart, Windlas Biotech ranks #429 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #429 out of 957 companies for Pretax Margin %. This puts Windlas Biotech in the upper half of its industry. The industry median Pretax Margin % is 7.48. Windlas Biotech's value of 9.24% is 23.5% above this benchmark. Historically, Windlas Biotech's own Pretax Margin % has ranged from 5.09 to 24.93 over the past decade. While the company's 10-year median is 10.20 vs. the industry median of 7.48, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.48, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Pretax Margin % of 9.24% is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Pretax Margin % is 9.24%, which is near median its own 10-year median of 10.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹978.98, compared to a current price of ₹990.95 — trading 1.2% above its estimated fair value. The current Pretax Margin % is 9.24%, which is near median its 10-year median of 10.20 and 23.5% above the Drug Manufacturers industry median of 7.48. Windlas Biotech's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Pretax Margin % is 9.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be overvalued.
The current stock price of ₹990.95 is trading 1.2% above its estimated GF Value™ of ₹978.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Pretax Margin %: 9.24% (near median its 10-year median of 10.20)
GF Value™: ₹978.98 vs. price of ₹990.95 (1.2% above fair value)
Industry Position: 23.5% above the Drug Manufacturers median (#429 of 957)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
88GF Score
Get the complete analysis for NSE:WINDLAS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
